{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biomerica, Inc.
Is Biomerica, Inc. technically bullish or bearish?
As of June 13, 2025, Biomerica, Inc. has shifted from mildly bullish to mildly bearish, influenced by bearish signals from the weekly MACD, Bollinger Bands, and moving averages, despite mixed monthly indicators.
Who are in the management team of Biomerica, Inc.?
As of March 2022, the management team of Biomerica, Inc. includes CEO Zackary Irani, Lead Independent Executive Vice Chairman Allen Barbieri, and Independent Directors Francis Cano, Catherine Coste, Jane Emerson, and Mark Sirgo, who oversee the company's operations and strategy.
What does Biomerica, Inc. do?
Biomerica, Inc. is a biomedical company that develops and markets medical diagnostic products for chronic diseases. As of February 2025, it has a market cap of $8.30 million, with net sales of $1 million and a net profit of -$1 million.
How big is Biomerica, Inc.?
As of Jun 18, Biomerica, Inc. has a market capitalization of 8.30 million, with net sales of 5.69 million and a net profit of -4.85 million over the latest four quarters. The company reported shareholder's funds of 6.59 million and total assets of 9.25 million as of May 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
